Reply to Gallieni et al. and Silver

The letters by Gallieni et al.¹ and Silver² regarding our paper³ both provided interesting insights into heterotopic ossification (HO) post spinal cord injury (SCI). It is a pleasure to be able to respond to thoughtful responses. We agree with the comments of Gallieni et al.¹ on the possible mechanism of warfarin treatment in preventing HO post SCI. The authors suggest that the positive effect of warfarin may be in response to its block on osteocalcin. Other studies have shown that warfarin's inhibition of osteocalcin leads to abnormal mineralization of bone matrix.^{4, 5, 6} Further, these studies suggest the effect of warfarin to be even more potent during embryonic stages of bone development. Hence, though warfarin may not directly impair mineralization of bone matrix, it has a potential role in disrupting the formation of mineral crystals on collagen microfibrils involved in bone development.

We also agree with the authors' comment that there is an increased risk of cardiovascular calcification due to warfarin; however, this is a complex relationship.¹ This risk has been shown to occur in certain individuals with specific genetic variations in their carboxylation enzymes.⁷ As cited by the letter of Gallieni et al.¹ and our article,³ this may lead to increased risk of hemorrhage.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account

Continue with Google

Continue with ORCiD